Advances in the development of bradykinin receptor ligands

Current Topics in Medicinal Chemistry

Volumn 6, Issue 13, 2006, Pages 1353-1363

  Fortin, Jean Philippe ^a,b   Marceau, François ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Aminopeptidase; Angiotensin II; B 9958; Docking site homology models; GCPR

Indexed keywords

3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; ACETYLLYSYLBRADYKININ[7 [3 (2 NAPHTHYL)ALANINE] 8 ISOLEUCINE 9 DEARGININE]; ANATIBANT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; B 10352; B 9430; B 9870; B 9958; BRADYKININ ANTAGONIST; BRADYKININ B1 RECEPTOR AGONIST; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR AGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ RECEPTOR AGONIST; BRADYZIDE; CU 201; DEXTRO ARGINYLBRADYKININ[3 HYDROXYPROLINE 5,8 [3 (2 THIENYL)ALANINE] 7 DEXTRO PHENYLALANINE]; FR 191413; ICATIBANT; JMV 1116; JMV 1431; LABRADIMIL; LIGAND; LOBRADIMIL; LONG ACTING DRUG; MEN 16132; NPC 17731; PEPTIDE DERIVATIVE; R 954; UNCLASSIFIED DRUG; UNINDEXED DRUG; [[4 [2 [[BIS(CYCLOHEXYLAMINO)METHYLENE]AMINO] 3 (2 NAPHTHYL)PROPIONAMIDO]PHENYL]METHYL]TRIBUTYLPHOSPHONIUM CHLORIDE;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BRAIN EDEMA; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HYPERALGESIA; INFLAMMATORY DISEASE; NONHUMAN; PAIN; PAW EDEMA; PHARMACOPHORE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; TISSUE DISTRIBUTION;

EID: 33746592402     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/15680266106061353     Document Type: Review

References (83)

1. Moreau, M.E.; Garbacki, N.; Molinaro, G.; Brown, N. J.; Marceau, F.; Adam, A. The kallikrein-kinin system: current and future pharmacological targets. J. Pharmacol. Sci. 2005, 99, 6-38.
2. 1 receptor for kinin. Pharmacol. Rev. 1998, 50, 357-386.
3. Blais, C.; Marceau, F.; Rouleau, J.-L.; Adam, A. The kallikrein-kininogen-kinin system: Lessons from the quantification of endogenous kinins. Peptides 2000, 21, 1903-1940.
4. Leeb-Lundberg, L.M.F.; Marceau, F.; Müller-Esterl, W.; Petitbone, D.J.; Zuraw, B.L. International union of Pharmacology. XLV. Classification of the kinin Receptor Family: from molecular Mechanisms to Pathophysiological consequences. Pharmacol. Rev. 2005, 57, 27-77.
5. 2 receptor antagonist FR173657 in models of visceral and cutaneous inflammation. Inflamm. Res. 2000, 49, 535-540.
6. Uknis, A. B.; DeLa Cadena, R.A.; Janardham, R.; Sartor, R.B.; Whalley, E.T.; Colman, R.W. Bradykinin receptor antagonists type 2 attenuate the inflammatory changes in peptidoglycan-induced acute arthritis in the Lewis rat. Inflamm. Res. 2001, 50, 149-155.
7. Samadfam, R.; Teixeira, C.; Bkaily, G.; Sirois, P.; de Brum-Fernandez, A.; D'Orléans-Juste, P. Contribution of B2 receptors for bradykinin in Arthus reaction-induced plasma extravasation in wild-type or B2 transgeníc knockout mice. Br. J. Pharmacol. 2000, 129, 1732-1738.
8. 2 bradykinin receptor antagonist with long-lasting oral activity in animal models of inflamatory hyperalgesia. Br. J. Pharmacol. 2000, 129, 77-86.
9. 1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 2004, 143, 803-818.
10. Marceau, F.; Regoli, D. Bradykinin receptor ligands: therapeutic perspectives. Nat. Rev. Drug Discov. 2004, 3, 845-852.
11. Boissonnas, R.A.; Guttmann, A.; Jaquenoud, P.A. Synthèse de la L-arginyl-L-propyl-L-propyl-glycyl-L-phenylalanyl-L-seryl-L- propyl-L-phenylalanyl-L-arginine, un ponapeptide présentant les propriétés de la bradykinine. Helv. Chim. Acta. 1960, 43, 1349-1355.
12. Elliott, D.F.; Horton, E.W. The structure of bradykinin-a plasma kinin from ox blood. Biochem. Biophys. Res. Commun. 1960, 3, 87-91.
13. Merrifield, R.B. Solid phase synthesis. III. An improved synthesis of bradykinin. Biochemistry 1964, 3, 1385-1390.
14. Regoli, D.; Barabé, J.; Park, W.K. Receptors for bradykinin in rabbit aortae. Can. J. Pharmacol. 1977, 55, 855-867.
15. Regoli, D.; Barabé, J.; Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 1980, 32, 1-46.
16. Vavrek, R.; Stewart, J.M. Competitive antagonists of bradykinin. Peptides 1985, 6, 161-164.
17. Lembeck, F.; Griesacher, T.; Eckhardt, M.; Menke, S.; Breipohl, G.; Knolle, J. New, long acting, potent bradykinin antagonists. Br. J. Pharmacol. 1991, 102, 297-304.
18. Amblard, M.; Daffix, I.; Bedos, P.; Bergé, G.; Pruneau, D.; Paquet, J.L.; Luccarini, J.M.; Bélichard, P.; Dodey, P.; Martinez, J. Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety. J. Med. Chem. 1999, 42, 4185-4192.
19. Doctrow, S.R.; Abelleira, S.M.; Curry, L.A.; Heller-Harrison, R.; Kozarich, J.W; Malfroy, B.; McCarroll, L.A.; Morgan, K.G.; Morrow, A.R.; Musso, G.F. The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvasculature endothelial cells. J. Pharmacol. Exp. Ther. 1994, 271, 229-237.
20. Kyle, D.J.; Blake, P.R.; Smithwick, D.; Green, L.M.; Martin, J.A.; Sinsko, J.A.; Summers, M.F. NMR and computational evidence that high-affinity bradykinin receptor antagonists adopt C-terminal β-turns. J. Med. Chem., 1993, 36, 1450-1460.
21. Jarnagin, K.; Bhakta, S.; Zuppan, P.; Yee, C.; Ho, T.; Phan, T.; Tahilramani, R.; Pease, J. H.; Miller, A.; Freedman, R. Mutations in the B2 bradykinin receptor reveal a different pattern of contacts for peptidic agonists and peptidic antagonists. J. Biol. Chem. 1996, 271, 28277-28286.
22. 1 receptor-related peptides: antagonist. Hypertension 1996, 28, 833-839.
23. 1 receptor antagonists with multi-enzymatic resistance properties. Can. J. Physiol. Pharmacol. 2002, 80, 287-292.
24. 1 receptor. Br. J. Pharmacol. 2000, 131, 885-892.
25. 1 receptors. Can. J. Physiol. Pharmacol. 1997, 74, 137-144.
26. Fortin, J.P.; Gera, L.; Bouthillier, J.; Adam, A.; Marceau F. Endogenous aminopeptidase N decrease the potency of peptide agonists and antagonists of thte kinin B1 receptors in the rabbit aorta. J. Pharmacol. Exp. Ther. 2005, 314, 1169-1176.
27. 9-kallidin-induced vasoconstrictor responses by metallopeptidase inhibition in isolated human umbilical artery. J. Pharmacol. Exp. Ther. 2005, 313, 1355-1360.
28. 1 receptor antagonism. J. Pharmacol. Exp. Ther. 2006, in press.
29. 1 receptors for kinins. J. Pharmacol. Exp. Ther. 1991, 259, 997-1003.
30. 1 receptors for kinins. Immunopharmacology 1995, 29, 141-147.
31. Stewart, J.M.; Gera, L.; Chan, D.C.; Whalley, E.T.; Hanson, W.L.; Zuzack, J.S. Potent, long-acting bradykinin antagonists for a wide range of applications. Can. J. Physiol. Pharmacol. 1997, 75, 719-724.
32. Chan, D.; Gera, L.; Stewart, J.; Helfrich, B.; Verella-Garcia, M.; Johnson, G.; Baron, A.; Yang, J.; Puck, T.; Bunn, P. Jr. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism. Proc. Natl. Acad. Sci. USA 2002, 99, 4608-4613.
33. Dziadulewicz, E.K. Non-peptide ligands for bradykinin receptors 1995-2004. Expert Opin. Ther. Patents. 2005, 15, 824-859.
34. 2 receptor. J. Med. Chem. 1993, 36, 2583-2584.
35. 2 receptor antagonist. Proc. Natl. Acad. Sci. USA 1994, 91, 4693-4697.
36. Salvino, J.M.; Seoan, P.R.; Dolle, R.E. Conformational analysis of bradykinin by annealed molecular dynamics and comparison to NMR derived conformations. J. Comput. Chem. 1993, 14, 438-444.
37. Sawutz, D.G.; Salvino, J.M.; Dolle, R.E.; Seoan, P.R.; Farmer, S.G. Pharmacology and structure activity relationships of the nonpeptide bradykinin receptor antagonist WIN 64338. Can. J. Physiol. Pharmacol. 1995, 73, 805-811.
38. Aramori, I.; Zenkoh, J.; Morikawa, N. Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657. Mol. Pharmacol. 1997, 51, 171-176.
39. 2R antagonist. 2. Overcoming the species difference between guinea pig and man. J. Med. Chem. 1998, 41, 4053-4061.
40. Abe, Y.; Kayakiri, H.; Satoh, S.; Inoue, T.; Sawada, Y.; Inamura, N.; Asano, M.; Aramori, I.; Hatori, C.; Sawai, H.; Oku, T.; Tanaka, H. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-α]pyridine moiety. J. Med. Chem. 1998, 41, 4062-4079.
41. 2 receptor antagonist, FR 173657. Br. J. Pharmacol. 1997, 120, 617-624.
42. 2 receptor antagonists incorporating the 4-heteroarylquinoline framework. Improvement of aqueous solutility and new insights into species difference. J. Med. Chem. 2004, 47, 1617-1630.
43. 2 receptor. J. Med. Chem. 2000, 43, 769-771.
44. 2 receptor antagonists. J. Med. Chem. 2002, 45, 2160-2172.
45. 2 receptor. Int. Immunopharmacol. 2003, 3, 1529-1536.
46. 2 receptor antagonist. Immunopharmacology 1999, 43, 187-194.
47. 2 receptor antagonist, reduces brain edema and improve long term neurological function recovery after closed head trauma in rats. J. Neurotrauma 2002, 19, 953-964.
48. 2 receptor antagonist: In vivo activity on bradykinin-induced bronchoconstriction and nasal mucosa microvascular leakage in anesthetized guinea pigs. J. Pharmacol. Exp. Ther. 2005, 315, 616-623.
49. Abe, Y.; Kayakiri, H.; Satoh, S.; Inoue, T.; Sawada, Y.; Inamura, N.; Asano, M.; Aramori, I.; Hatori, C.; Sawai, H.; Oku, T.; Tanaka, H. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation. J. Med. Chem. 1998, 41, 4587-4598.
50. Heitsch, H.; Wagner, A.; Schoelkens, B.A.; Wirth, K. Novel series of O-substituted 8-quinolines and 4-benzothiazoles as potent antagonists of the bradykinin B2 receptors. Bioorg. Med. Chem. Lett. 1999, 9, 327-332
51. 2 receptor. Mol. Pharmacol. 1997, 52, 16-20.
52. 2 receptor agonist (FR 190997) and antagonist (FR173657). Immunopharmacology 1999, 43, 179-185
53. 2 receptor ligands, incorporating the 4-aminoquinoline framework. I Identification of a key pharmacophore to determine species difference and agonist/antagonist profile. J. Med. Chem. 2004, 47, 2667-2677.
54. 2 receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-Picolyl)benzimidazole frameworks. J. Med. Chem. 2004, 47, 2853-2863.
55. 1 receptor antagonist. J. Am. Chem. Soc. 2003, 125, 7516-7517.
56. 1 receptor antagonist. Eur. J. Pharmacol. 2004, 499, 77-84.
57. 1 receptor: effects at the rabbit receptor. J. Pharmacol. Exp. Ther. 2004, 311, 1121-1130.
58. 1 receptor antagonist. J. Med. Chem. 2003, 46, 1803-1806.
59. 1 receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 2384-2388
60. 1 receptor: biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 2004, 309, 661-669.
61. 1 receptor antagonists and their actions in pain. Peptide Receptor Montreal 2004 Symposium. August 3, 2004.
62. 1 receptor based on a 2-alkylamino-5-sulfamoylbenzamide core. J. Med. Chem. 2004, 47, 4642-4644.
63. 1 receptor. Br. J. Pharmacol. 2005, 144, 889-899.
64. 1 receptor. Trends Pharmacol. Sci. 2005, 26, 116-118.
65. 1 receptors. Life Sci. 1992, 51, 125-129.
66. 2 receptors. Immunopharmacology 1996, 33, 186-190.
67. Stewart, J.M.; Gera, L.; Hanson, W.; Zuzack, J.S.; Burkard, M.; McCullough, R.; Whalley, E.T. A new generation of bradykinin antagonists. Immunopharmacology 1996, 33, 51-60.
68. 1 receptor antagonists. J. Med. Chem. 2000, 43, 2382-2386.
69. 2 receptors based on a postulated pharmacophore of existing nonpeptide antagonists. Biol. Chem. 2006, 387, 189-194.
70. Stewart, J.M.; Gera, L.; York, E.J.; Chan, D.C.; Bunn, P. Bradykinin antagonists: present progress and future prospects. Immunopharmacology 1999, 43, 155-161.
71. IA Angiotensin II receptor induces its constitutive activation. J. Biol. Chem. 1997, 272, 1822-1826.
72. 1 angiotensin receptor is generated by angiotensin II induction. Biochemistry 1996, 35, 16435-16442.
73. Leeb-Lundberg, L.M.; Kang, D.S.; Lamb, M.E.; Fathy, D.B. The human B1 bradykinin receptor exhibits high ligand-independent, constitutive activity. J. Biol. Chem. 2001, 276, 8785-8792.
74. 2 bradykinin receptor. J. Biol. Chem. 2001, 276, 41100-41111.
75. 1A angiotensin II receptor are involved in the differential recognition of peptide and nonpeptide ligands. Biochem. Biophys. Res. Commun. 1995, 209, 153-160.
76. Schambye, H.T.; Hjorth, S.A.; Weinstock, J.; Schwartz, T.W. Interaction between the nonpeptide angiotensin antagonist SKF-108, 566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor. Mol. Pharmacol. 1995, 47, 425-431.
77. 2 receptor and molecular modelling to define the pharmacophore of non-peptide bradykinin receptor antagonists. Biochem. Pharmacol. 2004, 67, 601-609.
78. 2 receptor: evidence from mutational analysis. Br. J. Pharmacol. 2003, 140, 500-506.
79. Ha, S.N.; Hey, P.J.; Ransom, R.W.; Harrell, C.M. Jr; Murphy, K.L.; Chang, R.; Chen, T.B.; Su, D.S.; Markowitz, M.K.; Bock, M.G.; Freidinger, R.M.; Hess, F.J. Binding modes of dihydroquinoxalinones in a homology model of bradykinin receptor 1. Biochem. Biophys. Res. Commun. 2005, 331, 159-166
80. 1 receptor. Mol. Pharmacol. 2006, 69, 1146-1157.
81. 1 receptor for therapeutic neovascularization. Circulation 2002, 105, 360-366.
82. 2 antagonist: icatibant in liver cirrhosis and hereditary angioedema, in Peptide Receptors Montreal 2004 Symposium, Montreal, Canada, 2004.
83. Emerich, D. F.; Dean, R.L.; Osborn, C.; Bartus, R.T. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation. Clin. Pharmacokinet. 2001, 40, 105-123.